Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

s in evaluating Oclaro's historical and prospective operating financial performance, as well as its operating performance relative to its competitors.

Adjusted EBITDAAdjusted EBITDA is calculated as net income/loss excluding the impact of income taxes, net interest income/expense, depreciation and amortization, net foreign currency translation gains/losses, as well as restructuring, acquisition and related costs, non-cash compensation related to stock and options, gain on bargain purchase, purchase accounting adjustments related to the fair market value of acquired inventories and certain other one-time charges and credits, including flood related advance payments received from insurers, impairment of fixed assets and inventory and related expenses, specifically identified in the non-GAAP reconciliation schedules set forth below. Oclaro uses Adjusted EBITDA in evaluating Oclaro's historical and prospective cash usage, as well as its cash usage relative to its competitors. Specifically, management uses this non-GAAP measure to further understand and analyze the cash used in/generated from Oclaro's core operations. Oclaro believes that by excluding these non-cash and non-recurring charges, more accurate expectations of its future cash needs can be assessed in addition to providing a better understanding of the actual cash used in or generated from core operations for the periods presented. Oclaro further believes that providing this information allows Oclaro's investors greater transparency and a better understanding of Oclaro's core cash position.

 OCLARO, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited, in thousands, except per share amounts)Three Months Ended December 29, 2012September 29, 2012December 31, 2011Revenues

$
59,465$
48,813$
86,488Cost of revenues

137,966130,97675,613Gross profit

21,49917,83710,875Operating expenses:Research and development

25,75025,76517,024Sellin
'/>"/>

SOURCE Oclaro, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
8. Kemwell Announces Successful Pre-NDA US FDA Inspection
9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The escalation ... proteins, is placing renewed emphasis on alternate delivery ... as a number of factors are converging to ... makers and their delivery device partners . These ... conditions, the growing trend toward self-administration for chronic ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... April 17, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. ... conducted Phase 2 clinical trials,of GVAX immunotherapy ... patients with advanced prostate cancer from these,studies ... responses to a broad array of prostate ...
... A 9-month, randomized,double-blind, parallel-group Phase II study of ... given daily to the currently,approved COPAXONE(R) 20 mg ... disease activity as measured by magnetic,resonance images (MRI) ... mg experienced a reduced mean on-trial relapse rate,of ...
Cached Medicine Technology:Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 2Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 3Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 2Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 3Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 5
(Date:5/19/2013)... (PRWEB) May 19, 2013 Passages Malibu, ... treatment center, has announced this week the launch of ... the brands’ social media channels. “We are always ... treatment community and to get feedback regarding sobriety, what’s ... CEO and co-founder of the Passages Addiction Treatment ...
(Date:5/19/2013)... 19, 2013 The AMTC team will be ... Columbus Georgia Convention & Trade Center on June 1st. Professionals ... AMTC auditions are free of charge. , Actors, Models and ... hundreds of successful artists and grads like Caitlin Kinney - ... Tombolini , Chris Young - on his Liquid Neon 2013 ...
(Date:5/19/2013)... May 19, 2013 The legal team ... YazSideEffects.com in a concerted effort to connect women and ... birth control drugs Yaz, Yasmin & Ocella with the ... of information on the notorious birth control drugs as ... Pharmaceuticals. , Yaz, Yasmin & Ocella were very ...
(Date:5/18/2013)... 19, 2013 In “Cooking with Spirits for ... , author Janet Hall Svisdahl’s new cookbook, readers are transported ... to make even the pickiest eater drool. “I dedicate this ... she explains. , Found within the 364 pages of ... of delicious recipes, from fast and simple to gourmet. Each ...
(Date:5/18/2013)... 19, 2013) Each year, the American Gastroenterological ... contributions and achievements in gastroenterology through its esteemed ... distinguished and talented individuals who work tirelessly to ... we are pleased to announce the 2013 recognition ... colleagues for their tremendous contributions to our field," ...
Breaking Medicine News(10 mins):Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Actors, Models and Talent for Christ Hosting Auditions in Columbus, GA June 1st in Search of Local Talent 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5
... , MOUNTAIN VIEW, CA (October 25, 2011) ... the first-time discovery of the potentially protective nature of ... to be protective against a high-risk leucine-rich repeat kinase ... The LRRK2 gene is recognized as a significant risk ...
... of blood proteins can predict which patients with the progressive ... at least five years or to die within two years, ... and Centocor R&D. The findings, published online last week in ... , could help doctors determine those patients in imminent ...
... TUESDAY, Oct. 25 (HealthDay News) -- Training parents in ... conduct of preschool children with symptoms of attention-deficit/hyperactivity disorder ... also found insufficient evidence to support the use of ... age, but two drugs are generally safe and effective ...
... -- Teens who don,t get enough sleep may find themselves putting ... for obesity, new research suggests. In the study, researchers surveyed ... and found that the average sleep time on weekdays was 6 ... females. The average sleep time on weekends was 9 hours 10 ...
... supplements eaten for four to six weeks prior to prostate ... -- the number of rapidly dividing cells -- in ... diet. Done by researchers at UCLA,s Jonsson Comprehensive Cancer ... the low-fat, fish oil supplement diet were able to change ...
... new study in the Journal of Bone and Joint ... lumbar disc symptoms were significantly worse if the patients had ... to those who had symptoms for six months or less. ... satisfaction. "Patients often ask their physicians whether ...
Cached Medicine News:Health News:23andMe discovers genetic variant that may protect those at risk for Parkinson's disease 2Health News:Blood proteins predict survival in idiopathic pulmonary fibrosis, Pitt-led team says 2Health News:Parental Training May Benefit ADHD Kids Under 6: Report 2Health News:Sleepy Teens More Prone to Weight Gain: Study 2Health News:You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells 2Health News:You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells 3Health News:You are what you eat: Low fat diet with fish oil slowed growth of human prostate cancer cells 4Health News:Surgical treatment within six months of lumbar disc herniation 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: